433
Participants
Start Date
July 31, 2016
Primary Completion Date
August 31, 2018
Study Completion Date
February 29, 2020
AQX-1125 100 mg
Synthetic SHIP1 activator
AQX-1125 200 mg
Synthetic SHIP1 activator
Placebo
Appearance and weight matched placebo tablets
Site 4004, Budapest
Site 1103, Edegem
Site 3002, Herlev
Site 4001, Csongrád
Site 1101, Roeselare
Site 1102, Ghent
Site 4003, Sopron
Site 9041, The Bronx
Site 9037, New Hyde Park
Site 9016, Brooklyn
Site 1402, Córdoba
Site 9066, Cheektowaga
Site 7002, Bucharest
Site 9036, Newtown
Site 9050, Bala-Cynwyd
Site 9031, Bryn Mawr
Site 9032, Philadelphia
Site 9038, Owings Mills
Site 7005, Bucharest
Site 9012, Richmond
Site 9045, Winston-Salem
Site 9058, Winston-Salem
Site 9002, Raleigh
Site 2003, Kolín
Site 1401, Aravaca
Site 9055, Wilmington
Site 9068, Morehead City
Site 9040, Greer
Site 2001, Pilsen
Site 9035, Homewood
Site 9027, Franklin
Site 7009, Bucharest
Site 9047, Gahanna
Site 9051, Toledo
Site 9048, Cleveland
Site 9033, Cleveland
Site 9013, Noblesville
Site 2006, Jablonec nad Nisou
Site 9020, Royal Oak
Site 9042, Troy
Site 9034, Grand Rapids
Site 2002, Hradec Králové
Site 9049, West Des Moines
Site 7004, Bucharest
Site 9072, Omaha
Site 2005, Uherské Hradiště
Site 9054, Metairie
Site 9007, Shreveport
Site 9064, Little Rock
Site 9053, Oklahoma City
Site 9071, Oklahoma City
Site 9052, Temple
Site 9069, Houston
Site 9030, Houston
Site 9026, Tucson
Site 9025, Albuquerque
Site 9011, Los Angeles
Site 9021, Los Angeles
Site 9019, Los Angeles
Site 9010, Beverly Hills
Site 9070, Whittier
Site 9046, Sherman Oaks
Site 9060, Escondido
Site 9003, San Diego
Site 9023, Murrieta
Site 9015, Orange
Site 9039, Palo Alto
Site 9008, Mountlake Terrace
Site 7006, Craiova
Site 7011, Craiova
Site 7007, Brasov
Site 7001, Târgu Mureş
Site 7003, Sibiu
Site 9004, Farmington
Site 9029, Middlebury
Site 9005, Boston
Site 9028, Watertown
Site 9062, Cranford
Site 9001, Edison
Site 1013, Kelowna
Site 1005, Brampton
Site 1006, Burlington
Site 1002, Kingston
Site 1003, Kitchener
Site 1015, Oakville
Site 1010, Toronto
Site 1017, Québec
Site 1017, Québec
Site 1016, Sherbrooke
Site 1008, Sherbrooke
Site 2007, Prague
Site 2004, Prague
Site 5005, Daugavpils
Site 5001, Jelgava
Site 5002, Liepāja
Site 5003, Riga
Site 5004, Riga
Site 1301, Rotterdam
Site 1302, The Hague
Site 6011, Bydgoszcz
Site 6009, Gdynia
Site 6004, Gdynia
Site 6005, Piaseczno
Site 6001, Poznan
Site 6007, Poznan
Site 6002, Siedlce
Site 6008, Warsaw
Site 6003, Warsaw
Site 7010, Bucharest
Site 7008, Bucharest
Site 1405, Elche
Site 1403, Vic
Site 8008, Plymouth
Site 8001, Sheffield
8005, Coventry
Site 8007, Wolverhampton
Site 8009, London
Site 8004, London
Site 8002, Reading
Site 8003, Wakefield
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
INDUSTRY